New approach aims to keep breast cancer treatment on track by protecting blood cells
NCT ID NCT07380646
Summary
This study is testing whether a drug called leucogen can prevent a serious side effect of breast cancer treatment. Researchers want to see if leucogen reduces severe drops in white blood cells (neutropenia) in early-stage breast cancer patients taking ribociclib with hormone therapy. The trial will enroll about 94 patients to evaluate if this preventive approach helps patients better tolerate their cancer treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.